Wealth Enhancement Advisory Services
CLRB icon

Wealth Enhancement Advisory Services’s Cellectar Biosciences CLRB Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-400
Closed -$31.7K – 2357
2023
Q3 		$31.7K Buy
+400
New +$23.6K ﹤0.01% 2178

Other funds holding CLRB

RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wealth Enhancement Advisory Services's CLRB Position: Q4 2023 in Review

Wealth Enhancement Advisory Services sold out of Cellectar Biosciences (CLRB) in Q4 2023, closing a stake of 400 shares — an estimated $31.7K sold.

Wealth Enhancement Advisory Services first reported a position in CLRB in Q3 2023 and held it in 1 quarter. The position peaked at $31.7K in Q3 2023. 26 funds tracked by Wall St. Rank hold CLRB as of Q4 2023.

  • Wealth Enhancement Advisory Services reported no remaining Cellectar Biosciences position as of Q4 2023 after selling out during the quarter.
  • Wealth Enhancement Advisory Services sold 400 Cellectar Biosciences shares in Q4 2023, an estimated $31.7K.
  • Wealth Enhancement Advisory Services first reported a position in Cellectar Biosciences in Q3 2023 and held it in 1 quarter.
  • Wealth Enhancement Advisory Services's Cellectar Biosciences position peaked at $31.7K in Q3 2023.
  • 26 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q4 2023.

Based on Wealth Enhancement Advisory Services's 13F filing for Q4 2023, filed 30 Jan 2024.